We are live on ! Find out more
LBRX

LB Pharmaceuticals
LBRX

77 hedge funds and large institutions have $692M invested in LB Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 31 increasing their positions, 14 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

121% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 14

100% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 10

25% more capital invested

Capital invested by funds: $552M → $692M (+$141M)

13% more funds holding

Funds holding: 68 → 77 (+9)

0.39% more ownership

Funds ownership: 97.99% → 98.38% (+0.39%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
77
Holders Change
+9
Holders Change %
+13.24%
% of All Funds
0.95%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
20
Increased
31
Reduced
14
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CP
Caligan Partners
New York
+$33.2M
2
NCM
Nantahala Capital Management
Connecticut
+$8.72M
3
SSC
Spruce Street Capital
New York
+$8.55M
4
NFGH
Nan Fung Group Holdings
Hong Kong
+$7.63M
5
GPP
Great Point Partners
Connecticut
+$6.92M

Top Sellers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
-$6.57M
2
Jennison Associates
Jennison Associates
New York
-$6.54M
3
JP Morgan Chase
JP Morgan Chase
New York
-$4.24M
4
Ameriprise
Ameriprise
Minnesota
-$1.97M
5
LF
Longbow Finance
Switzerland
-$1.83M
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
51
T. Rowe Price Associates
Maryland
$327K +$49.7K +2,155 +19%
Two Sigma Investments
52
Two Sigma Investments
New York
$314K – – –
MIM
53
MetLife Investment Management
New Jersey
$274K – – –
Invesco
54
Invesco
Georgia
$265K -$5.21K -226 -2%
SCM
55
Soleus Capital Management
Connecticut
$247K – – –
QC
56
Quadrature Capital
United Kingdom
$245K +$229K +9,931 New
Mirae Asset Global ETFs Holdings
57
Mirae Asset Global ETFs Holdings
Hong Kong
$226K +$4.71K +204 +2%
VGA
58
Vanguard Global Advisers
Pennsylvania
$216K +$202K +8,753 New
Wells Fargo
59
Wells Fargo
California
$213K -$316K -13,680 -61%
New York State Common Retirement Fund
60
New York State Common Retirement Fund
New York
$150K +$141K +6,100 New
PFSRSONJ
61
Police & Firemen's Retirement System of New Jersey
New Jersey
$149K +$37.3K +1,616 +37%
Citigroup
62
Citigroup
New York
$137K +$118K +5,134 +1,180%
SO
63
STRS Ohio
Ohio
$126K +$39.2K +1,700 +50%
Federated Hermes
64
Federated Hermes
Pennsylvania
$123K – – –
Barclays
65
Barclays
United Kingdom
$112K -$592K -25,685 -85%
BNP Paribas Financial Markets
66
BNP Paribas Financial Markets
France
$99.9K +$1.04K +45 +1%
Legal & General Group
67
Legal & General Group
United Kingdom
$42.5K -$3.58K -155 -8%
TRCT
68
Tower Research Capital (TRC)
New York
$41K +$6.92K +300 +22%
AIP
69
Ameritas Investment Partners
Nebraska
$38.5K – – –
California State Teachers Retirement System (CalSTRS)
70
California State Teachers Retirement System (CalSTRS)
California
$25.7K -$3.3K -143 -12%
SCM
71
Sterling Capital Management
North Carolina
$9.07K -$5.17K -224 -38%
GI
72
GAMMA Investing
California
$4K +$3.41K +148 +1,057%
PNC Financial Services Group
73
PNC Financial Services Group
Pennsylvania
$3.58K +$3.35K +145 New
MPWT
74
MassMutual Private Wealth & Trust
Connecticut
$1.33K +$1.25K +54 New
Carson Wealth (CWM LLC)
75
Carson Wealth (CWM LLC)
Nebraska
$715 +$484 +21 +263%
1 2
3
4

LBRX Hedge Fund Activity: Q1 2026 in Review

77 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in LB Pharmaceuticals (LBRX) for Q1 2026, worth a combined $692M — up 25% from $552M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new LBRX positions and 10 closed out — a net gain of 10 holders — while 31 added to existing stakes and 14 trimmed.

The largest buyer was Caligan Partners, opening a new position worth an estimated $33.2M. The largest seller was Logos Global Management, cutting an estimated $6.57M.

  • 77 institutional investors held LB Pharmaceuticals (LBRX) as of Q1 2026, up from 68 in Q4 2025.
  • Funds reported $692M of LB Pharmaceuticals stock for Q1 2026, up 25% quarter-over-quarter.
  • 20 funds opened new LB Pharmaceuticals positions in Q1 2026 and 10 closed out, a net change of +10 holders.
  • The largest LB Pharmaceuticals buyer in Q1 2026 was Caligan Partners, an estimated $33.2M added.
  • The largest LB Pharmaceuticals seller in Q1 2026 was Logos Global Management, an estimated $6.57M sold.

Based on aggregated 13F filings for Q1 2026.